We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Online ordering will be unavailable from 17:00 GMT on Friday, April 25 until 17:00 GMT on Sunday, April 27 due to maintenance. We apologise for the inconvenience.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Edited by
David M. Greer, Boston University School of Medicine and Boston Medical Center,Neha S. Dangayach, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System
Neuroprognostication, the focus of this book, is crucial toward the management of the highly complex patient in the neurological intensive care unit (Neuro ICU). It is of primary importance to understand the nature of the disease and the potential for recovery. Informed prognostication by neurologically trained physicians has been hypothesized to be a significant reason for the improved outcomes of neurological patients managed in a Neuro ICU versus general medical ICUs.[1]
Decisions surrounding withdrawal of life-sustaining therapies (WLST) are highly dependent on prognosis. In a retrospective study of Neuro ICU patients who were terminally extubated, family members surveyed most frequently cited quality of life, prognosis, and the patient’s previously known wishes as “very important” in their decision to remove life-sustaining therapy.[2]
Evidence-based prognostication in the Neuro ICU is difficult, and may be biased by the effect of WLST on patient mortality.
Neuromuscular diseases and respiratory failure are common problems encountered in both neurologic and medical intensive care units. Neuromuscular respiratory failure can be caused by diseases of the motor neuron, peripheral nerve, neuromuscular junction, or muscle. Thus, localization of the disorder is essential for adequate management.
One of the most frequent neurological consultations in any medical or surgical intensive care unit (ICU) is for generalized weakness. Patients admitted to ICUs may have a number of factors leading to neuromuscular problems, including metabolic derangements, nutritional deficiencies, acquired diseases, and structural problems of the neuromuscular system. Weakness in the setting of a critically ill patient can have profound effects on patient morbidity and mortality with increased length of hospital stay, medical complications, and cost [1]. In this chapter we have highlighted the various causes of generalized weakness in ICU patients, and the diagnostic approach and management of these illnesses.
Catheter-associated urinary tract infections (CAUTIs) are among the most common hospital-acquired infections (HAIs). Reducing CAUTI rates has become a major focus of attention due to increasing public health concerns and reimbursement implications.
OBJECTIVE
To implement and describe a multifaceted intervention to decrease CAUTIs in our ICUs with an emphasis on indications for obtaining a urine culture.
METHODS
A project team composed of all critical care disciplines was assembled to address an institutional goal of decreasing CAUTIs. Interventions implemented between year 1 and year 2 included protocols recommended by the Centers for Disease Control and Prevention for placement, maintenance, and removal of catheters. Leaders from all critical care disciplines agreed to align routine culturing practice with American College of Critical Care Medicine (ACCCM) and Infectious Disease Society of America (IDSA) guidelines for evaluating a fever in a critically ill patient. Surveillance data for CAUTI and hospital-acquired bloodstream infection (HABSI) were recorded prospectively according to National Healthcare Safety Network (NHSN) protocols. Device utilization ratios (DURs), rates of CAUTI, HABSI, and urine cultures were calculated and compared.
RESULTS
The CAUTI rate decreased from 3.0 per 1,000 catheter days in 2013 to 1.9 in 2014. The DUR was 0.7 in 2013 and 0.68 in 2014. The HABSI rates per 1,000 patient days decreased from 2.8 in 2013 to 2.4 in 2014.
CONCLUSIONS
Effectively reducing ICU CAUTI rates requires a multifaceted and collaborative approach; stewardship of culturing was a key and safe component of our successful reduction efforts.
This chapter reviews the pathology, epidemiology, treatment and management of Intracerebral hemorrhage and subarachnoid hemorrhage (SAH). Hypertensive intracerebral hemorrhages typically occur in territories perfused by deep perforating arteries coming off the basal cerebral arteries. The advent in early use of CT imaging, however, has documented expansion of intracerebral hemorrhage in almost 40% of the cases. The role of surgery for supratentorial hemorrhages has been extensively evaluated in the management of intracerebral hemorrhage, with most of these studies showing no benefit of surgical evacuation of the hematoma. There are approximately 25-30,000 patients a year with SAH. The initial management strategy for the patient after SAH is to stabilize the patient until the cerebral aneurysm can be identified and secured. Interventional procedures may be needed to open constricted cerebral blood vessels if medical maneuvers are insufficient to improve or prevent the onset of neurological deficits due to vasospasm.
Neuromuscular diseases and respiratory failure are common processes encountered in both neurologic and medical intensive care units. Problems can be encountered anywhere along the peripheral nervous system. Neurogenic respiratory failure can be localized to diseases of the motor neuron, peripheral nerve, neuromuscular junction, or muscle.
This chapter provides a broad overview of the clinical presentation of neuromuscular respiratory failure and reviews diagnostic criteria and treatment for specific neuromuscular diseases.
NEUROMUSCULAR RESPIRATORY FAILURE: CLINICAL FEATURES
Patients with neuromuscular respiratory weakness need to be closely followed with pulmonary function tests. These should include at least vital capacities, negative inspiratory forces, and expiratory flow volumes. Part of the need for close monitoring is due to the often unreliability of the clinical exam.
▪The clinical signs and symptoms of patients with neuromuscular failure may differ and can present with varying signs and symptoms of respiratory, bulbar, or appendicular weakness.
▪Patients may complain of dyspnea or a vague sense of uneasiness. Brow sweating is common.
▪In many circumstances a patient with neuromuscular failure will develop the typical signs and symptoms of respiratory difficulties (tachypnea, tachycardia, accessory muscle use, decreased cough, etc.).
A patient with a rapidly ascending paralysis, an acute dysautonomia, or neuromuscular junction inhibition may not be able to manifest the signs and symptoms typically encountered in a patient with impending respiratory arrest secondary to primarily pulmonary processes. Thus a decision on the timing of endotracheal intubation should be based on the decline of pulmonary function tests and not necessarily on the clinical presentation of the patient. In the above circumstances patients may appear well until the need for urgent intubation.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.